Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Paul Peter Tak Insider Profile
4 Followers
Paul Peter Tak, CEO, Director at Candel Therapeutics, holds 343.63K shares in Candel Therapeutics (Ticker: CADL).
Paul Peter Tak Candel Therapeutics (CADL)CEO, Director
Candel Therapeutics (CADL)
CEO, Director
Ranked #71,537 out of 99,335 Corporate Insiders
Profitable Transactions
2 out of 4 Profitable Transactions
Average Return
-16.40%
Average return per transaction
Time Frame
Compare to
Insider Roles
CEO, Director
Roles that Paul Peter Tak holds in companies
Most Profitable Insider Trade
The most profitable trade made by Paul Peter Tak
Paul Peter Tak's Trading History
List of latest transactions for each holding click on a transaction to see Paul Peter Tak's performance on stock
You May Also Like
Paul Peter Tak insider profile FAQ
What is the percentage of profitable transactions made by Paul Peter Tak?
The percentage of profitable transactions made by Paul Peter Tak is 50%.
What is the average return per transaction made by Paul Peter Tak?
The average return per transaction made by Paul Peter Tak is -16.40%.
What stocks does Paul Peter Tak hold?
Paul Peter Tak holds: CADL stocks.
What was Paul Peter Tak’s latest transaction?
Paul Peter Tak latest transaction was an Uninformative Buy of $20.00K.
What was Paul Peter Tak's most profitable transaction?
Paul Peter Tak’s most profitable transaction was an Informative Sell of CADL stock on July 15, 2024. The return on the trade was 27.00%.
What is Paul Peter Tak's role in Candel Therapeutics?
Paul Peter Tak's role in Candel Therapeutics is CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.